WallStreetZenWallStreetZen

NASDAQ: LSTA
Lisata Therapeutics Inc Stock

$3.53+0.16 (+4.75%)
Updated Jun 21, 2024
LSTA Price
$3.53
Fair Value Price
$2.76
Market Cap
$29.33M
52 Week Low
$1.95
52 Week High
$3.90
P/E
-1.43x
P/B
0.68x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.05M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$19M
Beta
0.56
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

LSTA Overview

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LSTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LSTA ($3.53) is overvalued by 27.86% relative to our estimate of its Fair Value price of $2.76 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LSTA ($3.53) is not significantly undervalued (27.86%) relative to our estimate of its Fair Value price of $2.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LSTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LSTA due diligence checks available for Premium users.

Be the first to know about important LSTA news, forecast changes, insider trades & much more!

LSTA News

Valuation

LSTA fair value

Fair Value of LSTA stock based on Discounted Cash Flow (DCF)
Price
$3.53
Fair Value
$2.76
Overvalued by
27.86%
LSTA ($3.53) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LSTA ($3.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LSTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LSTA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.43x
Industry
-5.75x
Market
30.75x

LSTA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.68x
Industry
6.2x
LSTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LSTA's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
LSTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$48.2M
Liabilities
$5.5M
Debt to equity
0.13
LSTA's short-term assets ($47.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LSTA's short-term assets ($47.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LSTA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LSTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.0M
Investing
$6.4M
Financing
-$142.0k
LSTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LSTA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
LSTA$29.33M+4.75%-1.43x0.68x
NKGN$29.62M-0.83%-0.26x-0.54x
PMN$28.63M-2.58%-2.04x371.36x
BIVI$28.62M+1.08%-0.50x1.51x
BOLT$28.60M+1.90%-0.45x0.27x

Lisata Therapeutics Stock FAQ

What is Lisata Therapeutics's quote symbol?

(NASDAQ: LSTA) Lisata Therapeutics trades on the NASDAQ under the ticker symbol LSTA. Lisata Therapeutics stock quotes can also be displayed as NASDAQ: LSTA.

If you're new to stock investing, here's how to buy Lisata Therapeutics stock.

What is the 52 week high and low for Lisata Therapeutics (NASDAQ: LSTA)?

(NASDAQ: LSTA) Lisata Therapeutics's 52-week high was $3.90, and its 52-week low was $1.95. It is currently -9.49% from its 52-week high and 81.03% from its 52-week low.

How much is Lisata Therapeutics stock worth today?

(NASDAQ: LSTA) Lisata Therapeutics currently has 8,307,433 outstanding shares. With Lisata Therapeutics stock trading at $3.53 per share, the total value of Lisata Therapeutics stock (market capitalization) is $29.33M.

Lisata Therapeutics stock was originally listed at a price of $11,562.50 in Mar 1, 1999. If you had invested in Lisata Therapeutics stock at $11,562.50, your return over the last 25 years would have been -99.97%, for an annualized return of -27.66% (not including any dividends or dividend reinvestments).

How much is Lisata Therapeutics's stock price per share?

(NASDAQ: LSTA) Lisata Therapeutics stock price per share is $3.53 today (as of Jun 21, 2024).

What is Lisata Therapeutics's Market Cap?

(NASDAQ: LSTA) Lisata Therapeutics's market cap is $29.33M, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lisata Therapeutics's market cap is calculated by multiplying LSTA's current stock price of $3.53 by LSTA's total outstanding shares of 8,307,433.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.